Press Releases

Cambrex Acquires IEP GmbH

 

EAST RUTHERFORD, N.J., March 22 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM) announced it has acquired IEP GmbH (“IEP”), a privately held company that is a leader in the field of industrial biocatalysis.  IEP is located in Wiesbaden, Germany and offers cost effective customized biocatalytic process development and sales of enzymes to the pharmaceutical industry, with the ability to utilize its tool box of over 100 proprietary biocatalytic enzymes.  IEP “bioreduction” technologies have been successfully used in numerous commercialized processes.

“In combination with our existing chiral chemistry business, the acquisition of IEP will result in Cambrex being able to offer a broad biocatalysis platform to the pharmaceutical industry.  We are very excited about the future growth of this business, as IEP has demonstrated the introduction of a “green” biocatalytic step in chemical synthesis that can provide significant benefits resulting in the cost efficient, commercial scale production of enantiomerically pure chemical products and intermediates.  IEP has assembled, under the leadership of Dr. Antje Gupta, a strong group of highly skilled scientists and built a successful business based on its proprietary technology and intellectual property.  We are looking forward to working with the IEP team to expand their business development efforts through the existing Cambrex channels to market,” commented Steven Klosk, President & CEO of Cambrex Corporation.

The business will be renamed Cambrex IEP and will remain in Wiesbaden, Germany.  For more information on IEP, please visit www.biocatalysis.com.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule active pharmaceutical ingredients (“APIs”), advanced intermediates and other products for branded and generic pharmaceuticals.  The Company currently employs approximately 850 people worldwide.  For more information, please visit www.cambrex.com.

SOURCE Cambrex Corporation

>To order reprints of this article, click here: Reprints

Copyright 2009 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

TheStreet Premium Services

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
Dow Jones S&P 500 NASDAQ 10-Year Note
12,393.45 1,310.33 2,827.34 15.81
Oil *
101.78
DOWN
26.41
DOWN
2.99
DOWN
10.02
DOWN
0.44
10 Yr
1.58%
SPDR Gold
151.62
-0.21%
-0.23%
-0.35%
-2.71%
Data delayed 20 minutes

Top Stories and Tools

Articles From

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet